Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Saved in:
| Title: | Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. |
|---|---|
| Authors: | Mok, Tony S.1, Cheng, Ying2, Zhou, Xiangdong3, Lee, Ki Hyeong4, Nakagawa, Kazuhiko5, Niho, Seiji6, Chawla, Alka7, Rosell, Rafael8, Corral, Jesus9, Migliorino, Maria Rita10, Pluzanski, Adam11, Noonan, Kay12, Tang, Yiyun13, Pastel, Malaika14, Wilner, Keith D.13, Wu, Yi-Long15 syylwu@live.cn |
| Source: | Drugs. Feb2021, Vol. 81 Issue 2, p257-266. |
| Database: | SPORTDiscus with Full Text |
Be the first to leave a comment!
